Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUR-928 in COVID-19 with Acute Organ Injury
NCT04447404Phase 2Terminated
- Sponsor
- DURECT Corporation
- Start
- Sep 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of larsucosterol in coronavirus disease 2019 (COVID-19), acute kidney injury (AKI), acute liver injury (ALI), pneumonia, sponsored by DURECT Corporation. Started Sep 2020; status: terminated.
02
Drugs
larsucosterol
03
Conditions
coronavirus disease 2019 (COVID-19)acute kidney injury (AKI)acute liver injury (ALI)pneumonia
Beyond the preview
Go deeper on NCT04447404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447404.